Fox Run Management’s bluebird bio BLUE Stock Holding History

Fox Run Management’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,167	Closed	-$74.2K	–	701
2023 Q1	$74.2K	Buy	+1,167	New	+$133K	0.02%	611
2022 Q4	–	Sell	-1,047	Closed	-$133K	–	633
2022 Q3	$133K	Buy	+1,047	New	+$118K	0.05%	526
2021 Q3	–	Sell	-760	Closed	-$315K	–	472
2021 Q2	$315K	Buy	+760	New	+$301K	0.29%	153
2020 Q1	–	Sell	-406	Closed	-$462K	–	147
2019 Q4	$462K	Buy	406 +210	+107%	+$228K	0.37%	57
2019 Q3	$234K	Buy	+196	New	+$299K	0.21%	243
2018 Q3	–	Sell	-446	Closed	-$908K	–	585
2018 Q2	$908K	Buy	+446	New	+$1.02M	0.29%	48
2017 Q4	–	Sell	-340	Closed	-$604K	–	675
2017 Q3	$604K	Sell	340 -324	-49%	-$453K	0.17%	223
2017 Q2	$903K	Buy	+664	New	+$801K	0.31%	54
2016 Q2	–	Sell	-656	Closed	-$361K	–	543
2016 Q1	$361K	Buy	+656	New	+$403K	0.24%	164

Other funds holding BLUE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Fox Run Management's BLUE Position: Q2 2023 in Review

Fox Run Management sold out of bluebird bio (BLUE) in Q2 2023, closing a stake of 1,167 shares — an estimated $74.2K sold.

Fox Run Management first reported a position in BLUE in Q1 2016 and held it in 9 quarters. The position peaked at $908K in Q2 2018. 175 funds tracked by Wall St. Rank hold BLUE as of Q2 2023.

Fox Run Management reported no remaining bluebird bio position as of Q2 2023 after selling out during the quarter.
Fox Run Management sold 1,167 bluebird bio shares in Q2 2023, an estimated $74.2K.
Fox Run Management first reported a position in bluebird bio in Q1 2016 and held it in 9 quarters.
Fox Run Management's bluebird bio position peaked at $908K in Q2 2018.
175 funds tracked by Wall St. Rank held bluebird bio as of Q2 2023.

Based on Fox Run Management's 13F filing for Q2 2023, filed 11 Aug 2023.